AtriCure, Inc. develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, the Asia-Pacific, and internationally.
The company offers Isolator Synergy Clamps, a single-use disposable radio frequency product; multifunctional pens and linear ablation devices, single-use disposable RF products for the treatment of cardiac arrhythmias; and the cryoICE Cryoablation System, which enables the user to make linear ablations of varied lengths.
Additionally, AtriCure provides EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation. It also offers the cryoSPHERE probe, which provides temporary pain relief by applying cryothermic energy to targeted intercostal peripheral nerves in the ribcage.
The company features the AtriClip System, an implantable device coupled to a single-use disposable applier; the LARIAT System, a solution for soft-tissue closure; Lumitip dissectors to separate tissues to provide access to key anatomical structures targeted for ablation; Glidepath guides for placement of clamps; and Subtle Cannulas to support access for EPi-Sense catheters.
In addition, the company sells various reusable cardiac surgery instruments. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.